An Update on Stiripentol Mechanisms of Action : A Narrative Review
© 2024. The Author(s)..
Stiripentol (Diacomit®) (STP) is an orally active antiseizure medication (ASM) indicated as adjunctive therapy, for the treatment of seizures associated with Dravet syndrome (DS), a severe form of childhood epilepsy, in conjunction with clobazam and, in some regions valproic acid. Since the discovery of STP, several mechanisms of action (MoA) have been described that may explain its specific effect on seizures associated with DS. STP is mainly considered as a potentiator of gamma-aminobutyric acid (GABA) neurotransmission: (i) via uptake blockade, (ii) inhibition of degradation, but also (iii) as a positive allosteric modulator of GABAA receptors, especially those containing α3 and δ subunits. Blockade of voltage-gated sodium and T-type calcium channels, which is classically associated with anticonvulsant and neuroprotective properties, has also been demonstrated for STP. Finally, several studies indicate that STP could regulate glucose energy metabolism and inhibit lactate dehydrogenase. STP is also an inhibitor of several cytochrome P450 enzymes involved in the metabolism of other ASMs, contributing to boost their anticonvulsant efficacy as add-on therapy. These different MoAs involved in treatment of DS and recent data suggest a potential for STP to treat other neurological or non-neurological diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 05. März, Seite 1351-1371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bacq, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
56-12-2 |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-024-02813-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369334779 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369334779 | ||
| 003 | DE-627 | ||
| 005 | 20240326235712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-024-02813-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM369334779 | ||
| 035 | |a (NLM)38443647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bacq, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Update on Stiripentol Mechanisms of Action |b A Narrative Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Stiripentol (Diacomit®) (STP) is an orally active antiseizure medication (ASM) indicated as adjunctive therapy, for the treatment of seizures associated with Dravet syndrome (DS), a severe form of childhood epilepsy, in conjunction with clobazam and, in some regions valproic acid. Since the discovery of STP, several mechanisms of action (MoA) have been described that may explain its specific effect on seizures associated with DS. STP is mainly considered as a potentiator of gamma-aminobutyric acid (GABA) neurotransmission: (i) via uptake blockade, (ii) inhibition of degradation, but also (iii) as a positive allosteric modulator of GABAA receptors, especially those containing α3 and δ subunits. Blockade of voltage-gated sodium and T-type calcium channels, which is classically associated with anticonvulsant and neuroprotective properties, has also been demonstrated for STP. Finally, several studies indicate that STP could regulate glucose energy metabolism and inhibit lactate dehydrogenase. STP is also an inhibitor of several cytochrome P450 enzymes involved in the metabolism of other ASMs, contributing to boost their anticonvulsant efficacy as add-on therapy. These different MoAs involved in treatment of DS and recent data suggest a potential for STP to treat other neurological or non-neurological diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cytochrome P450s | |
| 650 | 4 | |a Epilepsy | |
| 650 | 4 | |a GABA | |
| 650 | 4 | |a Ion channels | |
| 650 | 4 | |a Lactate dehydrogenase | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Stiripentol | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a stiripentol |2 NLM | |
| 650 | 7 | |a R02XOT8V8I |2 NLM | |
| 650 | 7 | |a Dioxolanes |2 NLM | |
| 650 | 7 | |a gamma-Aminobutyric Acid |2 NLM | |
| 650 | 7 | |a 56-12-2 |2 NLM | |
| 700 | 1 | |a Depaulis, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Castagné, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Le Guern, Marie-Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Wirrell, Elaine C |e verfasserin |4 aut | |
| 700 | 1 | |a Verleye, Marc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 4 vom: 05. März, Seite 1351-1371 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:05 |g month:03 |g pages:1351-1371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02813-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 05 |c 03 |h 1351-1371 | ||